<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260376</url>
  </required_header>
  <id_info>
    <org_study_id>M-20100221</org_study_id>
    <nct_id>NCT01260376</nct_id>
  </id_info>
  <brief_title>Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise</brief_title>
  <official_title>Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate free fatty acid and VLDL-TG metabolism before and during exercise&#xD;
      with and without pharmacological antilipolysis by the niacin antagonist Acipimox. Main&#xD;
      focuses will be VLDL-TG and free fatty acid metabolism as well as expression of membrane&#xD;
      proteins in fat- and muscle biopsies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance in liver and skeletal muscle is of central pathogenic significance in the&#xD;
      development of type 2 diabetes. The molecular connections are unresolved but high levels of&#xD;
      free fatty acids and triglyceride is probably involved. Diabetic subjects and to a lesser&#xD;
      extent obese subjects have increased triglyceride levels, this could be due to an abnormal&#xD;
      turnover of VLDL-TG. It is not yet investigated whether VLDL-TG kinetics changes during&#xD;
      pharmacological antilipolysis. Using the aseptic ex-vivo labeling technique (developed in our&#xD;
      laboratories) we will investigate this issue in sedentary healthy men. After a 3 hour basal&#xD;
      period subjects will exercise on a bike for 60 minutes at 60% of VO2max. In both basal and&#xD;
      exercise period one muscle and one fat biopsy will be obtained, further blood samples will be&#xD;
      drawn to examine FFA and VLDL-TG metabolism etc..&#xD;
&#xD;
      This new knowledge will contribute to the understanding of metabolic disorders like type 2&#xD;
      diabetes and obesity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of exercise and antilipolysis on FFA and VLDL-TG kinetics</measure>
    <time_frame>6 hour investigation day</time_frame>
    <description>Healthy untrained men, investigated with pharmacological antilipolysis by Acipimox (Olbetam) and placebo on 2 occasions. Each day consists of 3 hour basal period and 90 minutes exercise on a bicycle at 60% of VO2-maximum. During the day glucose and lipid metabolism is investigated by glucose and VLDL tracer, as well as indirect calorimetrics. Cellular signaling is investigated by 2 muscle- and 2 fat biopsies each day.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Acipimox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo tablets will be administered 4 times previous to and during the investigation day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acipimox</intervention_name>
    <description>Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day</description>
    <arm_group_label>Acipimox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - healthy, untrained males&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  medication&#xD;
&#xD;
          -  history of malignancy, alcohol abuse or drug abuse&#xD;
&#xD;
          -  participation in isotope trials in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soren Nielsen, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Aarhus, Norrebrogade</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Aarhus, Norrebrogade</name>
      <address>
        <city>Aarhus</city>
        <zip>8</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>September 17, 2012</last_update_submitted>
  <last_update_submitted_qc>September 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Birgitte Nellemann</investigator_full_name>
    <investigator_title>MD PhD student</investigator_title>
  </responsible_party>
  <keyword>VLDL-TG</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Exercise</keyword>
  <keyword>Free Fatty Acids</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

